U.S. health authorities said Thursday that 16- and 17-year-olds should get a booster dose of Pfizer's COVID-19 vaccine once they're six months past their last shot.
The U.S. and many other nations already were urging adults to get booster shots to pump up immunity that can wane months after vaccination, calls that intensified with the discovery of the worrisome new omicron variant.
On Thursday, the Food and Drug Administration gave emergency authorization for 16- and 17-year-olds to get a third dose of the vaccine made by Pfizer and its partner BioNTech. And hours later, the Centers for Disease Control and Prevention lifted the last barrier — saying those teens should get their booster as soon as it's time.
CDC Director Rochelle Walensky told The Associated Press the boosters are important considering that protection against infection wanes over time and “we’re facing a variant that has the potential to require more immunity to be protected.”
“Vaccination and getting a booster when eligible, along with other preventive measures like masking and avoiding large crowds and poorly ventilated spaces, remain our most effective methods for fighting COVID-19,” Dr. Janet Woodcock, acting FDA commissioner, said in a statement.
The Pfizer vaccine is the only option in the U.S. for anyone younger than 18, either for initial vaccination or for use as a booster. It’s not yet clear if or when teens younger than 16 might need a third Pfizer dose.
Vaccinations for children as young as 5 just began last month, using special low-dose Pfizer shots. By this week, about 5 million 5- to 11-year-olds had gotten a first dose.
The extra-contagious delta variant is causing nearly all COVID-19 infections in the U.S., and in much of the world. It’s not yet clear how vaccines will hold up against the new and markedly different omicron mutant. But there’s strong evidence that boosters offer a jump in protection against delta-caused infections, currently the biggest threat.
Complicating the decision to extend boosters to 16- and 17-year-olds is that the Pfizer shot -- and a similar vaccine made by Moderna -- have been linked to a rare side effect. Called myocarditis, it’s a type of heart inflammation seen mostly in younger men and teen boys.
The FDA said rising COVID-19 cases in the U.S. mean the benefits of boosters greatly outweighed the potential risk from the rare side effect, especially as the coronavirus itself can cause more serious heart inflammation.
Health officials in Israel, which already gives boosters to teens, have said the side effect continues to be rare with third doses.
A U.S. study this week offered additional reassurance. Researchers from children’s hospitals around the country checked medical records and found the rare side effect usually is mild and people recover quickly. The research was published Monday in the journal Circulation.
___
Associated Press reporter Matthew Perrone contributed to this report.
Amazon plans to launch its first prototype satellites for Project Kuiper, an internet-from-space venture, in 2022. It's the first major step in the e-commerce giant's plan to rival SpaceX by building a network of satellites in space, providing internet to rural, underserved communities around the world. Loren Grush, senior science reporter for the Verge, discusses the project and how it could transform internet access moving forward.
The FDA is assessing whether the Moderna vaccine can cause heart problems in adolescents. Professor Peter Pitts, founder of the Center for Medicine in the Public Interest and former FDA Associate Commissioner, discusses what the FDA is looking into and what it means for the millions of kids yet to be vaccinated.
Pfizer posted an earnings beat in its third quarter, with revenue soaring over 134% thanks to solid Covid-19 vaccine sales. Pfizer also raised its outlook for the full-year, expecting revenue to surpass $80 billion. Peter Andersen, CEO & founder of Andersen Capital Management, joined Cheddar Movers to discuss.
Cheddar gets a look at Curiosity Stream's 'Ancient Oceans'; Deep-sea biologist Heather Bracken-Grissom sheds light on some of the monsters that we can and cannot explain lurking in the darkness of the ocean's depths; Tim Janssen, CEO of Sofar Ocean, discusses Sofar Ocean's latest round of Series B funding, and how Sofar Ocean is helping connect all five oceans to help everything from climate change to the global shipping industry.
Tim Janssen, CEO of Sofar Ocean, joins 'Cheddar Reveals' to discuss Sofar Ocean's latest round of Series B funding, and how Sofar Ocean is helping connect all five oceans to help everything from climate change to the global shipping industry.
Deep-sea biologist Heather Bracken-Grissom joins 'Cheddar Reveals' to shed light on some of the monsters that we can and cannot explain lurking in the darkness of the ocean's depths.
Leaders around the world have come together to discuss plans to bring action towards the Paris Agreement along with solutions on how to solve the evolving climate change crisis at the COP26 Summit. President and CEO of Center for International Environmental Law Carroll Muffett, joined Cheddar to discuss more.
Rachel Cleetus, the policy director and lead economist of the climate and energy program for the Union of Concerned Scientists, joined Cheddar to break down some of the key goals from the COP26 summit and why leaders must focus on the science of climate change instead of getting bogged down by petty politics and the fossil fuel industry. "The main thing they have to do, make sure we're cutting our emissions sharply within this decade because the science shows that we have to cut global emissions in half by 2030 if we're going to meet our goals of averting some of the most catastrophic impacts of climate change," she said.
Coastal cities around the world are grappling with sea level rise. And building a seawall? Not so fast. While a sea wall can be effective in certain scenarios, it can make the effects of sea level rise worse. That’s why municipalities are looking into creative alternatives.
